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Abstract The prohormone convertase PC2 is one of the major
subtilisin/kexin-like enzymes responsible for the formation of
small bioactive peptides in neural and endocrine cells. This
convertase is unique among the members of the subtilisin/kexin-
like mammalian serine proteinase family in that it undergoes
zymogen processing of its inactive precursor proPC2 late along
the secretory pathway and requires the help of a PC2-specific
binding protein known as 7B2. We hypothesized that some of
these unique properties of PC2 are dictated by the presence of
PC2-specific amino acids, which in the six other known
mammalian convertases are otherwise conserved but distinct.
Accordingly, six sites were identified within the catalytic segment
of PC2. Herein we report on the site-directed mutagenesis of
Tyr194 and of the oxyanion hole Asp309 and the consequences of
such mutations on the cellular expression and enzyme activity of
PC2. The data show that the Y194D mutation markedly
increases the ex vivo ability of PC2 to process proopiomelano-
cortin (POMC) into L-endorphin in cells devoid of 7B2, e.g.
BSC40 cells. In these cells, expression of native PC2 does not
result in the secretion of measurable in vitro activity against a
pentapeptide fluorogenic substrate. In contrast, secreted Y194D-
PC2 exhibited significant enzymatic activity, even in the absence
of 7B2. Based on co-immunoprecipitations and Western blots,
binding assays indicate that Tyr194 participates in the interaction
of PC2 with 7B2, and that the oxyanion hole Asp309 is critical
for the binding of proPC2 with pro7B2.
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1. Introduction
Biologically inactive protein precursors often undergo lim-
ited proteolysis to generate one or more bioactive polypep-
tide(s). Processing usually occurs at speci¢c single or paired
basic residues [1] and is accomplished by one or more of the
seven known members of the family of serine proteinases of
the subtilisin/kexin type [2^4]. Phylogenetic structural analyses
of the catalytic domain of the prohormone convertases (PCs)
revealed that PC2 is the most conserved member of the family
[4]. All PCs are ¢rst synthesized as zymogens (proPCs) which
undergo autocatalytic processing of their prosegment within
the endoplasmic reticulum (ER), with the exception of
proPC2, which is processed to PC2 within the trans Golgi
network (TGN)/immature secretory granule (ISG) compart-
ments [2,5^7]. Of all the PCs, only PC2 requires a speci¢c
binding protein, known as 7B2 [2,8], and such binding im-
proves the e⁄ciency of zymogen activation of proPC2 to
PC2 [2,9^12]. The PC2-speci¢c binding protein 7B2 is itself
¢rst synthesized as a 186 amino acid (aa) precursor pro7B2186
[13], which is cleaved within the TGN by a furin-like enzyme
into the 150-aa 7B2150 [14]. It has been proposed that at least
two PC2-binding sites exist in pro7B2186. The ¢rst one resides
in the C-terminal (CT) 31-aa peptide, which is also a potent
PC2-speci¢c inhibitor containing a critical Lys-Lys sequence
[15,16], whereas the second one [10] may encompass a poly-
proline-containing segment (aa 88^95) [17]. The oxyanion hole
Asp309* [18], which is an Asn* in all other PCs as well as in
subtilases [1^4], has been reported to be important in the
initial binding of proPC2 to pro7B2186 within the ER [11].
However, the other PC2 residues involved in the binding of
7B2 are not known.
Our goal is to delineate in PC2 the critical amino acids
which play a key role in its zymogen activation and in its
concomitant binding to pro7B2/7B2. Thus, we hypothesized
that some of the special properties of PC2 are due to the
presence of speci¢c residues within its catalytic segment (aa
109^455) [18] which are unique to this convertase, and which
are otherwise di¡erent but conserved in all other PCs. Accord-
ingly, alignment of the catalytic segments of all the mamma-
lian PCs, revealed 9 positions where the above criteria were
satis¢ed (not shown). These include Ser189 in PC2 [18] which
is an Asn in all other PCs (Ser189Asn), Tyr194Asp,
Ala219Asn, Gln242Gly, Asn273Asp, the oxyanion hole
Asp309Asn, Met325Ile, Ser380Thr, and Val445Leu. Since
the last three replacements are conservative, only the ¢rst
six substitutions were considered. In this report, we isolated
vaccinia virus recombinants (VV:) of mouse PC2-mutants
generated by site-directed mutagenesis of Tyr194 and Asp309.
Following cellular expression of VV:recombinants, in the
presence or absence of VV:7B2 or VV:POMC, we analysed
the consequential e¡ects of the selected PC2 mutants on
proPC2 processing to PC2, their binding to pro7B2186/
7B2150, their ability to generate L-endorphin from its pre-
cursor, POMC, and their in vitro activity.
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2. Materials and methods
2.1. Mutagenesis and the generation of recombinant vaccinia viruses
Mutagenesis of Tyr194 of mPC2 [18] into either Tyr194Asp, Tyr194-
Leu or Tyr194Ala was performed by an asymmetric polymerase chain
reaction (PCR) technique, which relies on two PCR reactions using a
sense wild type and one of three overlapping antisense mutant oligo-
nucleotides [19]: sense 5P-GACCCCTACCCATACCCTCGATA-3P ;
and antisense 5P-TATCTCGGGTATGG(GTC; GAG; GGC)GG-
GGTC-3P for Tyr194 to Asp, Leu or Ala mutations, respectively. Re-
combinant vaccinia viruses (VV:) were then generated. The VV:PC2-
D309N [5,11], VV:pro7B2186 (consisting of aa 1^186) [13,14]
and VV:7B2150 (consisting of aa 1^150) [13,22] were previously re-
ported.
2.2. Cellular infections, metabolic labeling and immunoprecipitations
The constitutively secreting green monkey kidney BSC40 cells and
the endocrine pituitary somatolactotroph GH4C1 cells were infected
with the vaccinia virus recombinants VV:mPC2 or its mutants,
VV:m7B2, or VV:mPOMC (provided by G. Thomas, Vollum Insti-
tute, Portland, OR, USA) as described [5,10,11]. Following VV infec-
tions (2 pfu/cell, for each recombinant) and 17-h incubations, the cells
were pulse-labeled with either [35S]methionine or Na2[35SO4]. Immu-
noprecipitations under denaturing [5] or non-denaturing [10,11] con-
ditions were then performed on media and cell extracts. The antibod-
ies used were a C-terminally directed mPC2 fusion protein antibody
[5], a 7B2 antibody directed against the segment 23^39 [8] and a
L-endorphin-recognizing antibody [20]. The immunoprecipitates were
separated by SDS-PAGE followed by autoradiography. For L-endor-
phin immunoreactivity, gel lanes were sliced every 1 mm and eluted in
radioimmunoassay (RIA) bu¡er where analysis was performed [20].
2.3. In vitro activity of PC2
Enzymatic activity was assessed using the £uorogenic synthetic pep-
tide substrate pERTKR-MCA [21] as follows: the enzyme prepara-
tion (usually 5 Wl) was added to the assay reaction mixture consisting
of 50 mM sodium acetate (pH 5) and 5 mM CaCl2. The reaction (in a
total volume of 100 Wl) was initiated at room temperature by the
addition of pERTKR-MCA to a ¢nal concentration of 0.1 mM. Flu-
orescence was monitored every 30 min over 4 h, as described [21].
3. Results
3.1. Zymogen processing of PC2 and its Tyr194 and Asp309
mutants
In this work, we generated vaccinia virus recombinants of
the mutants Y194D, Y194L, and Y194A, as well as D309N.
The ¢rst two mutants represent the substitutions of Tyr194
observed in other PCs and in kexin, respectively, whereas
the Y194A mutant represents a neutral amino acid substitu-
tion. Analyses of the cellular expression of PC2 and its mu-
tants were done in constitutively secreting BSC40 cells and in
the regulated GH4C1 cell line (Fig. 1). Following a 30-min
pulse labeling with [35S]methionine and a chase of 180 min in
the absence of label, we note the intracellular presence of both
proPC2 and PC2 in both cell lines, although as previously
reported for native PC2 [5], proPC2 predominates over PC2,
especially in BSC40 cells. We also document that Y194D-
proPC2 and Y194D-PC2 migrate slightly slower than the na-
tive enzyme. Furthermore, we observe the presence of a PC2
doublet in GH4C1 cells, which may represent either heteroge-
neous glycosylation or alternative processing at the secondary
cleavage site within the pro-segment [5]. However, even
though in all cases the intracellular levels of proPC2 and/or
PC2 are similar, in the medium the level of accumulation of
either proPC2 (BSC40 cells) or PC2 (GH4C1 cells) is by far
highest for the Y194D mutant (see overexposed BSC40 me-
dia). The much higher level of secreted [35S]methionine-la-
beled proPC2 or PC2 from both cell types could be due either
to a higher rate of exit of Y194D-proPC2 from the ER, which
is known to be limiting [5,23,24] and/or to its preferred exit
from the TGN and secretion from the cell.
In order to di¡erentiate between the above two alternatives,
BSC40 cells expressing PC2 and its mutants were labeled with
Na2[35SO4] for 90 min (Fig. 2A), and, in order to compare the
rate of proPC2 to PC2 processing of the native vs. that of the
Y194D mutant, these cells were also pulse-labeled for 15, 45,
and 90 min (Fig. 2B). This choice of pulse times and type of
label was based on the documented slow exit of proPC2 from
the ER [5,23,24], and on the knowledge that protein sulfation
occurs in the TGN [25]. In BSC40 (Fig. 2A,B) and GH4C1
(not shown) cells, we noted the presence of sulfate-labeled
PC2 and/or proPC2 in all cases, demonstrating that PC2 as
well as its mutant isoforms reach the TGN. Since the levels of
secreted sulfated proPC2 and/or PC2 are very low (even after
17 days of exposure), in order to see all of the bands we had
to overexpose the ¢lm, using an HP ScanJet 6100C Scanner
and the Adobe Photoshop 4.0.1 program. The data (Fig. 2A;
Media) revealed that only the native, Y194D, and D309N
35SO4-labeled enzymes signi¢cantly accumulate PC2 in the
medium, whereas the Y194L and Y194A mutants mostly se-
crete proPC2 from BSC40 cells. It is also evident that at all
pulse times proPC2 to PC2 conversion is more e¡ective for
the Y194D mutant than for native PC2 (Fig. 2B). Remark-
ably, as estimated by densitometric scanning of ¢lms, the per-
cent total radioactivity of sulfated proPC2 and/or PC2 se-
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Fig. 1. Biosynthesis of PC2 and its Tyr194 and Asp309 mutants.
(Left) BSC40 or (Right) GH4C1 cells were infected with VV:re-
combinants of either native PC2, or its mutants Y194A, Y194D,
Y194L, D309N at a multiplicity of 2 plaque forming units/cell (pfu/
cell). Following overnight culture, the cells were washed and then
pulse-labeled for 30 min (p30) with [35S]methionine, and then chased
for 180 min (c180) in absence of radiolabel, as described [5]. Cell
extracts and media were subjected to immunoprecipitation with a
C-terminal PC2 antibody [5], analysed by SDS-PAGE (8% T, 2.7%
C), and £uorographed as described [5]. At the bottom, a BSC40 me-
dia autoradiogram obtained after 4 days of exposure (as opposed to
1 day) is also presented, in order to emphasize the low level of se-
cretion of proPC2 from either native PC2, or its Y194A, Y194L
and D309N mutants. The migration positions of proPC2 and PC2
are indicated. In the media of GH4C1 cells, native PC2 is secreted
both as a 71-kDa partially processed PC2 and a 68-kDa fully proc-
essed PC2 [5]. Notice that the Y194D-PC2 and Y194D-proPC2 mi-
grate slightly slower than the other isoforms in both cell extracts
and media. This may be due to a structural and/or negative charge
di¡erence caused by the mutation.
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creted into the medium is about equal (10^12% at p90) for
both Y194D-PC2 and native PC2. We therefore suggest that
the major reason for the comparatively much higher accumu-
lation of proPC2 and/or PC2 in the medium of cells express-
ing the Y194D-PC2 mutant (Fig. 2) is not due to a di¡erential
exit rate from the TGN. Unfortunately, in view of the limited
sensitivity of proPC2 to endoglycosidase H treatment [5], we
could not use this type of digestion to compare the rate of exit
of proPC2 and its mutant from the ER. Thus, we can only
speculate that the Y194D mutant may fold more e⁄ciently in
the ER than native proPC2 [26].
Interestingly, although the percent of total of 35SO4-labeled
proPC2 and/or PC2 secreted into the medium of the Y194D
mutant is about equal to that of native PC2 (i.e. 11 þ 1%; Fig.
2A), it is at least 12-fold higher in the case of [35S]methionine-
labeled proPC2 and/or PC2 (Fig. 1). This may be due to the
fact that the cellular sulfotransferase(s) is present in limiting
amounts, and that vaccinia virus infections signi¢cantly re-
duce the overall levels of endogenous proteins [5]. Indeed,
analysis of total sulfate labeled proPC2 and PC2 at 5 h vs.
17 h post infection revealed that the ratio of [35SO4]/
[35S]methionine is higher at 5 h post infection (not shown).
In order to further test the fate of PC2 and its mutants we
analysed by Western blots the molecular forms of PC2 ob-
tained from BSC40 and GH4C1 cells infected with the corre-
sponding vaccinia virus recombinants. Intracellularly, the lev-
els of proPC2 and/or PC2 were about the same for all
infections (not shown). Moreover, only the native-, Y194D-
and D309N-PC2 exhibited the presence of signi¢cant amounts
of PC2 in the media of either cell type, with notably higher
levels in the case of the Y194D-PC2. These data con¢rmed
that the di¡erences observed in our previous biosynthetic ex-
periments (Figs. 1 and 2) are not due to variable infection
e⁄ciencies, but rather re£ect the intrinsic properties of each
enzyme isoform.
3.2. Comparative ex vivo and in vitro bioactivity of PC2 and its
Tyr194 and Asp309 mutants
The composite picture deduced from the above data (Figs.
1 and 2) suggests that the level of proPC2 to PC2 conversion
is highest for the Y194D mutant, followed by the native en-
zyme and then by the D309N mutant. Both the Y194A and
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Fig. 2. Zymogen processing of PC2 and its Tyr194 and Asp309 mu-
tants. BSC40 cells were infected with VV:recombinants of either na-
tive PC2, or its mutants Y194A, Y194D, Y194L, and D309N at a
multiplicity of 2 pfu/cell. Following overnight culture, the cells were
washed and then pulse-labeled with Na2[35SO4] for either (A)
90 min, or (B) 15 (p15), 45 (p45) or 90 (p90) min. Cell extracts (C)
and media (M) were subjected to immunoprecipitation with a C-ter-
minal PC2 antibody [5] and analysed by SDS-PAGE as in Fig. 2.
Table 1
POMC processing by native PC2 and its Tyr194 and Asp309 mutants in BSC40 and GH4C1 cells
BSC40 cells
Enzyme Cells Media % of total L-end-sized product
POMC L-End POMC L-End
POMC Wt 1076 9 134 0 0.1%
PC2 1279 12 368 42 3.1%
Y194D 1637 250 236 1243 44.3%
Y194L 1158 12 256 0 0.1%
Y194A 745 20 160 0 0.1%
D309N 1123 10 357 0 0.1%
GH4C1 cells
Enzyme Cells Media % of total L-end-sized product
POMC/LPH L-End POMC/LPH L-End
POMC Wt 5903 96 2718 1 1.1%
PC2 5702 646 1596 786 16.4%
Y194D 5016 659 1658 1186 21.7%
Y194L 3798 79 1198 115 3.7%
Y194A 2745 91 1026 3 2.3%
D309N 3334 310 1218 1227 25.2%
L-Endorphin RIAs were performed on SDS-PAGE-puri¢ed fractions. The total immunoreactivity of [POMC] (2U106 BSC40 cells) or [POMC+L-
LPH] (2U106 GH4C1 cells)-related fractions was compared to that of L-endorphin-sized products. The numbers represent pg of immunoreactive
L-endorphin/pooled fraction estimated from duplicate experiments. The % of total L-endorphin-sized products is obtained by the sum of the
L-endorphin-sized immunoreactivity (cells+medium) divided by the total immunoreactivity. In BSC40 cells, we only observed POMC and
L-endorphin, whereas in GH4C1 cells L-LPH is additionally present due to the endogenous presence of PACE4 [2]. Co-expression of POMC
with the wild type (Wt) vaccinia virus is presented as control.
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Y194L mutants exhibit drastically reduced levels of PC2. In
order to test the intracellular enzyme activity of each PC2
isozyme, we co-expressed the substrate proopiomelanocortin
(POMC) with PC2 or its mutants in either BSC40 or GH4C1
cells, neither of which endogenously express PC1 or PC2 [2].
Cell extracts and media obtained from 6 h post overnight
infections were ¢rst fractionated on SDS-PAGE gels. Each
lane was then sliced into 1-mm sections and the eluted poly-
peptides analysed using a L-endorphin-speci¢c RIA (Table 1).
Clearly, in BSC40 cells only the Y194D mutant and, to a
lesser extent, native PC2 exhibit signi¢cant L-endorphin con-
verting activity above background in this constitutively secret-
ing cell line. In contrast, in the regulated GH4C1 cells, which
endogenously express large amounts of 7B2 [2], the D309N,
Y194D and native PC2 show similar activities. However, as in
BSC40 cells, the Y194L and Y194A seem inactive. These data
suggest that the intracellular environment of GH4C1 cells is
favorable for the expression of active D309N, Y194D and
native PC2, whereas in BSC40 cells only the Y194D isoform
is signi¢cantly active.
In order to test whether 7B2 is one of the major factors
contributing to the productive activation of PC2 and its mu-
tants, we next compared the processing of POMC by the
native PC2 and Y194D-PC2 in the presence or absence of
7B2 in BSC40 cells (Table 2). The data demonstrate that co-
expression of PC2 or its Y194D mutant with 7B2150, lacking
the C-terminal inhibitory CT-peptide [15], increase the level of
L-endorphin produced by about 8- and 2-fold, respectively.
Thus, our data suggest that only the Y194D mutant can ex-
hibit signi¢cant activity in the absence of 7B2, and that 7B2
increases the level of enzymatically active native- and Y194D-
PC2. Co-expression of 7B2150 and POMC with either Y194L-
or Y194A-PC2 did not result in signi¢cant L-endorphin con-
verting activity (not shown).
We also analysed the in vitro enzymatic activity of secreted
PC2 isozymes, using the £uorogenic pentapeptide (py-
roE)RTKR-MCA. Of the media obtained from native PC2-
or mutant PC2-expressing BSC40 cells, only that of Y194D-
PC2 exhibited detectable activity (0.2 pmol/minU106 cells). In
contrast, in the presence of co-expressed 7B2150 (as well as
pro7B2186), both native- (5.5 pmol/minU106 cells) and
Y194D-PC2 (2.5 pmol/minU106 cells) were able to cleave
the pentapeptide substrate. However, and in agreement with
the data of Figs. 1 and 2, triplicate Western blot analyses
demonstrated that the level of 68-kDa PC2 was much higher
in the case of the Y194D mutant as compared to the native
enzyme (not shown). Accordingly, in the presence of co-ex-
pressed 7B2, the calculated speci¢c activities demonstrated a
6-fold higher value for native PC2 (2.5 pmol/min/integrated
level of 68 kDa PC2U106 cells) as compared to Y194D-PC2
(0.4 pmol/min/integrated level of 68 kDa PC2U106 cells).
When 7B2150 was added exogenously to the medium of native
PC2 expressing cells, we still did not detect any activity (not
shown). In contrast, addition of 7B2150 to the medium of
Y194D-PC2 resulted in a substantial reduction in the loss of
enzymatic activity observed over time (not shown). This sug-
gests that, as reported for native PC2 [26], 7B2 can stabilize
the Y194D-PC2 activity and protect it from inactivation at
pH 5.
3.3. Binding of 7B2 to PC2 and its Tyr194 mutants
We previously reported that the D309N mutation decreases
the ability of proPC2 to bind pro7B2 within the ER, but still
allows binding of 7B2 and PC2 within the TGN/ISG [10].
Accordingly, we co-expressed in BSC40 cells either full length
7B2 (pro7B2186) or the N-terminal 150-aa 7B2 (7B2150)
lacking the CT-peptide [15,22], together with either native
PC2, its Tyr194 or its Asn309 mutants. Analyses of the inter-
actions of pro7B2/7B2 with proPC2 and/or PC2 were per-
formed on SDS-PAGE-fractionated immunoprecipitated
[35S]methionine-labeled 7B2-containing complexes under
non-denaturing conditions (Fig. 3). These data con¢rmed
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Fig. 3. Binding of 7B2 to PC2 and its Tyr194 mutants. Autoradio-
grams of SDS-PAGE slab gels (12% T; 1.3% C) of immunoprecipi-
tated media and extracts of BSC40 cells infected with VV:pro7B2186
or VV:7B2150 and VV:PC2, its Asp309 or Tyr194 mutants (each at
1 pfu/cell), obtained following a pulse of 2 h with [35S]methionine.
Immunoprecipitation reactions were done under non-denaturing
conditions using a 7B223ÿ39 antibody [8]. The positions of proPC2,
PC2, pro7B2 and 7B2 are emphasized, as well as those of the mo-
lecular weight markers. Controls consisted of cells individually in-
fected with either native VV:PC2, 7B2150, or pro7B2186. In the me-
dia, most of the protein migrating just above pro7B2 seems to be
non-speci¢c since we can also observe this band in the absence of
7B2 (Wt).
Table 2
POMC processing by native PC2 and its Y194D mutant in BSC40 cells in the absence or presence of 7B2150
BSC40 cells
Enzyme Cells Media % of total L-end-sized product
POMC L-End POMC L-End
POMC PC2/Wt 305 0 178 51 9.5%
PC2/7B2150 735 172 155 2144 72.2%
Y194D/Wt 817 46 124 612 41.1%
Y194D/7B2150 531 248 103 2195 79.4%
Similar to Table 1, the values represent pg of immunoreactive L-endorphin/pooled fraction (estimated from duplicate experiments) obtained from
the cells and media of BSC40 cells expressing either native- or Y194D-PC2 together with 7B2150 and POMC or Wt and POMC (control).
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that pro7B2186 and 7B2150 (doublets in BSC40 cells; [10,11])
co-immunoprecipitate with native PC2 and proPC2. Further-
more, in the medium Y194D-PC2 selectively binds pro7B2186
and does not bind to 7B2150. In addition, the Y194L- and
Y194A-proPC2 and/or PC2 only weakly bind pro7B2186 and
much less so 7B2150 (see medium of Fig. 3). This strongly
suggests that Tyr194 is critical for the e¡ective interaction of
PC2 with 7B2150. The data also reveal that whereas pro7B2186
and 7B2150 interact preferentially with the native pro-enzyme,
they prefer binding to the mature enzyme in the D309N mu-
tant, even though proPC2 predominates in the cells and media
(Fig. 1). Thus, the oxyanion hole Asp309 seems to enhance the
interaction of proPC2 with pro7B2186. Finally the above re-
sults were independently con¢rmed by Western blot analysis
using a PC2-speci¢c antiserum (not shown). Thus, the data in
Fig. 3 suggest that Tyr194 participates in the interaction of
mature PC2 with 7B2150, and that Asp309 improves the bind-
ing of proPC2 to pro7B2186.
4. Discussion
Characterization of the repertoire of dibasic processing en-
doproteases within endocrine and neural cells revealed that
PC1 and PC2 are the major enzymes responsible for the proc-
essing of most polypeptide hormone precursors into bioactive
peptides [1^4]. Biosynthetic analyses demonstrated that except
for PC2, all other PCs tested undergo zymogen processing
within the ER. Indeed, autocatalytic proPC2 to PC2 conver-
sion is a late event which starts in the TGN and continues in
the ISG (reviewed in [2^4]). The observation that PC2 is
weakly active in constitutively secreting cells, but is quite po-
tent in regulated cells, led to the identi¢cation of an intra-
cellular PC2-speci¢c binding protein, 7B2 [2,10^12,15^17].
Thus, PC2 exhibits at least two regulatory mechanisms. The
¢rst implicates its pro-segment which acts as an intramolecu-
lar chaperone guiding the folding of the enzyme which, when
cleaved, acts as an intermolecular inhibitor. The second in-
volves the participation of pro7B2/7B2 which regulate the
intracellular location and time at which PC2 becomes opti-
mally active. In contrast, the activity of PC1 is regulated by its
inhibitory pro-segment and C-terminal sequence [27].
In this work, we pursued our systematic investigation of the
critical residues involved in the regulation of the enzymatic
activity of PC2 and of its binding to 7B2 [10,11]. We hypothe-
sized that PC2 must contain unique residues which are re-
sponsible for its special properties. Of the six candidate amino
acids within the catalytic domain, the oxyanion hole Asp309
and Tyr194 caught our attention. The former had previously
been reported to a¡ect the pH optimum of the proPC2 to PC2
processing [28]. In addition, some of our previous data sug-
gested that the D309N mutation markedly diminished the
interaction of pro7B2 with proPC2 in the ER [10,11]. Our
present study further shows that the D309N mutation dramat-
ically decreases the ability of PC2 to process POMC into L-
endorphin in cells devoid of 7B2 (Table 1). However, in
GH4C1 cells which endogenously express 7B2, or in BSC40
cells co-infected with VV:7B2150, the D309N-mutant is active
and still exhibits a pH optimum of 5.0 (not shown). Since the
pro-segment of PC2 is expected to be a very potent inhibitor
of this enzyme, as reported for subtilases [1,3], it likely inter-
acts with residues lining the catalytic pocket of PC2. In ac-
cordance to such a model, the preferential interaction of
7B2150 with the mature form of PC2 observed for the
D309N mutant (Fig. 3) suggests that this mutation a¡ected
the intramolecular binding of the pro-segment of PC2 to its
catalytic pocket in such a way as to diminish the ability of
7B2150 to interact with proPC2. Upon autocatalytic cleavage
of the pro-segment, a possible conformational change may
then explain the observed similar binding of both pro7B2186
and 7B2150 to mature D309N-PC2 (Fig. 3). In contrast, for
native PC2, pro7B2 and 7B2 are both able to interact with
proPC2 (Fig. 3), suggesting that they can compete with the
pro-segment of PC2 for the catalytic domain.
Turning our attention to the second candidate position in
PC2, namely Tyr194, the data revealed that the Y194D muta-
tion did not cause an earlier zymogen activation of Y194D-
PC2 as compared to native PC2. Indeed, we observed no
POMC maturation nor processing of proPC2 to PC2 when
BSC40 cells infected with VV:Y194D-PC2 in the presence or
absence of VV:POMC were pulse labeled for 3 h with
[35S]methionine at 20‡C (not shown), a temperature which
prevents exit of PC2 from the TGN [11]. Furthermore, our
data clearly show that Y194D-PC2 is enzymatically active,
even in the absence of 7B2, both ex vivo where it still prefer-
entially cleaves POMC into L-endorphin (Tables 1 and 2) and
in vitro. In the presence of 7B2, the speci¢c activity of the
Y194D-PC2 is about 6-fold less than that of native PC2. This
suggests that stabilization of PC2 into its active conformation
by 7B2 is most e⁄cient for native PC2 [26]. Interestingly, the
Y194D mutation also resulted in an increased level of basal
secretion of PC2, suggesting that aside from a¡ecting the
overall ability of PC2 to interact with 7B2, Tyr194 may also
in£uence its intracellular level.
Pro7B2186 selectively binds to Y194D-PC2, as opposed to
7B2150 which does not bind to this enzyme (Fig. 3). This
suggests that the inhibitory CT-peptide of pro7B2186 cannot
compete with the pro-segment of this mutant, whereas it can
with native-PC2 and less so with D309N-PC2. Our data thus
reveal that Tyr194 is critical for the binding of PC2 to 7B2150,
possibly via the latter’s proline rich Src homology 3 (SH3)-like
segment [16]. SH3 domains are structurally well-characterized
as monomeric or dimeric modular units of protein structure
that mediate protein-protein recognition in numerous signal
transduction proteins (reviewed in [29]). Interestingly, the pol-
yproline sequence DP(Y/D)PXPRY(T/D) surrounding PC2’s
Tyr194, or Asp194 found in all the other PCs bears some sim-
ilarity to the SH3-like sequence YPDPPNPCP found within
7B2 (aa 88^95; [24]) and reported to be critical for its binding
to PC2 [16]. A common characteristic of SH3 domain binding
sites is the presence of the core motif PXXPX(R) [30]. In PC2,
the critical 7B2-binding sequence seems to center around the
motif PYPYPR (this work); whereas in 7B2 it is PDPPNP
[16]. The identi¢ed polyproline structure in PC2 may thus play
a critical role in the binding of PC2 to 7B2, presumably via an
essential hydrophobic interaction of Tyr194.
In evolutionary terms, it is tempting to speculate that the
presumed ancestral form of PCs [4] may have had a hydro-
phobic/aliphatic amino acid at the position equivalent to aa
194 and an Asn at position 309 (e.g. yeast kexin (Leu) and
subtilisin BPNP (Val)). Point mutations into either Asp194/
Asn309 or Tyr194/Asp309 may have led to two branches of
convertases: (i) the Asp194/Asn309 family which includes the
enzymes PC1, Furin, PACE4, PC4, PC5 and PC7 which have
not been shown to require a speci¢c binding protein; (ii) the
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Tyr194/Asp309 family which so far only includes PC2, would
have lost its ability to function without the help of an acces-
sory binding protein. Thus, it is probable that a regulatory
advantage was conferred to PC2 by its speci¢c binding to 7B2,
allowing it to be optimally active in its presence and virtually
inactive in its absence (Tables 1 and 2). This interaction would
tightly couple the regulation of PC2 activity to the level of
7B2 expression, thus ensuring that PC2 becomes active only at
the necessary location and to the required extent.
In conclusion, the data presented in this work reinforce the
notion that the highly conserved structure of PC2 evolved to
retain speci¢c amino acids which, together with the participa-
tion of 7B2, ensure the proper spatial and temporal function-
ing of PC2. Future work targeting the other unique PC2 res-
idues should further elucidate the complex regulatory
mechanisms of PC2 folding, activation and cellular localiza-
tion.
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